Catalyst Wire Dossier Catalyst Wire Dossier

RP7214

RP7214 · Rhizen Pharmaceuticals SA
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RP7214, covering 2022-04-21 to 2022-04-21. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection. [Phase 2]

See pricing